This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by WEILY, H. S. Articles by GENTON, E. Search for Related Content PubMed PubMed Citation Articles by WEILY, H. S. Articles by GENTON, E.

(Circulation. 1970;42:967.)
© 1970 American Heart Association, Inc.

---

Altered Platelet Function in Patients with Prosthetic Mitral Valves Effects of Sulfinpyrazone Therapy

HUGH S. WEILY M.D.¹ EDWARD GENTON M.D.¹

¹ From the Division of Cardiology, Department of Medicine, University of Colorado Medical Center, Denver, Colorado.

Platelet survival time and platelet adhesiveness and aggregation were examined in 16 patients with prosthetic mitral valves. Subsequently, nine patients were treated with sulfinpyrazone in doses of 400 mg and 800 mg/day, and the studies were repeated after a treatment period of 5 to 8 weeks. ⁵¹Chromium survival time was shortened in 15 of 16 patients, and the mean value for the entire group was 5.49 ± 0.23 days (normal, 6.73 ± 0.21 days; P < 0.001). Mean platelet adhesiveness in glass bead columns was 53 ± 5% (normal, 30 to 60%). Platelet aggregation (turbidometric technic of Born) was normal. Treatment with 400 mg of sulfinpyrazone daily reduced platelet adhesiveness to 40 ± 5% (P < 0.05), but effected no change in platelet survival time or platelet aggregation. Therapy with 800 mg of sulfinpyrazone daily corrected platelet survival time to normal, 6.68 ± 0.57 days (P < 0.01), but it produced no further decrease in adhesiveness and no change in aggregation. It is concluded that platelet abnormalities regularly occur in patients with prosthetic mitral valves and may contribute to thromboembolism in this group. Platelet survival time is a more sensitive measure of altered platelet kinetics than platelet adhesiveness or platelet aggregation. Therapy with 800 mg of sulfinpyrazone per day corrects demonstrated abnormalities and may be useful for prevention of thromboembolism in patients with prosthetic mitral valves.

Key Words: Thromboembolism • Platelet adhesiveness • Platelet survival time • Platelet aggregation

Submitted on June 8, 1970
Accepted on July 23, 1970

This article has been cited by other articles:

				D. N. Salem, D. Hartnett Daudelin, H. J. Levine, S. G. Pauker, M. H. Eckman, and J. Riff Antithrombotic Therapy in Valvular Heart Disease Chest, January 1, 2001; 119(1_suppl): 207S - 219S. [Full Text] [PDF]

				J. Zimmerman, T. T. Hirose, F. S. Folk, A. A. Bakst, and C. P. Bailey Reconstruction of the Cardiac Valves with Autologous Tissue Vascular and Endovascular Surgery, March 1, 1976; 10(2): 99 - 120. [PDF]

				M. Stefanini, J. S. Curtis, and J. J. Walsh Intravascular Hemolysis and Consumption Coagulop- Athy in Defective Aortic Valve Prosthesis. Transient, Beneficial Effect of Heparin and Recovery Following Successful Replacement of Valve Vascular and Endovascular Surgery, March 1, 1972; 6(2): 69 - 78. [PDF]